MMJ Recs

MARCH 20, 2024

Many dispensaries also offer additional services such as educational resources, patient consultations, and ongoing support programs to address patient concerns and enhance their overall treatment experience.

Dispensary 52

Dispensary Programs Access Patients 52

Veriheal

FEBRUARY 21, 2023

Despite notable advances in MMJ research over the last decade, scientists have found that some states’ restrictions on qualifying conditions prevent millions of patients from getting the treatments they need—robbing them of potential relief offered by cannabinoid therapies. How Do MMJ Restrictions Affect Patients and Doctors?

Access 98

Access Patients Chronic Pain Conditions 98

Cannabis Law Report

JULY 29, 2021

These assets include 5 addiction treatment clinics across the province of Alberta that have conducted over 35,000 patient visits during the past 12 months. Each clinic employs a highly educated and specialized team of dedicated physicians, nurses and therapists working in unison with patients to ensure treatment goals are achieved.

Chronic Pain 105

Chronic Pain Treatment Therapy Patients 105

Cannabis Law Report

JUNE 23, 2021

In addition to the pilot program, the parties are working toward an exclusive, definitive supply and distribution agreement, which, if entered into, is expected to position Medicann as the sole supplier and distributor of the RYAH Smart Dry Herb Inhalers in the region. to reach 3.2 billion euros ($3.75 billion) by 2025. Client Relations. +1

Programs 100

Programs Data Events Collective 100

MMJ Recs

MARCH 6, 2024

Over time, increasing public support, coupled with mounting scientific evidence, has led to a significant shift in attitudes, paving the way for greater acceptance and accessibility of medical marijuana as a legitimate treatment option.

Marijuana 52

Marijuana Chronic Pain Patients Treatment 52

Cannabis Law Report

SEPTEMBER 10, 2021

This exciting partnership between these innovative startups aims to advance patient access to psychedelic treatments in Europe, and improve the quality of the psychedelic medicines produced in Europe. We look forward to working closely with the Clerkenwell Health team to advance our psychedelic drug programs through clinical trials.”.

Research and Development 104

Research and Development Clinical Trials Therapy Environment 104

MMJ Recs

DECEMBER 26, 2022

Small lifestyle changes and simple exercises can often help; in addition, MMJ treatment can be highly effective for treating chronic pain (read more on how to apply for your NJ MMJ card below). Oftentimes, it’s far better to speak to an expert in handling chronic pain to ensure that you get the best treatment for your symptoms.

Chronic Pain 52

Chronic Pain Patients Treatment Therapy 52

Cannabis Law Report

AUGUST 7, 2022

In recent years, as more clinical trial results show that psychedelics can be used in conjunction with therapy to treat illnesses like depression and post-traumatic stress disorder, legislators pushed to make certain substances available in certain settings. Psychedelic Alpha Policy Map. Where Laws Are Changing.

Law 74

Law Research and Development Therapy Treatment 74

Veriheal

JUNE 21, 2023

If approved by the Food and Drug Administration (FDA), this psychedelic would be used to treat chronic and life-threatening mental disorders, especially for patients with limited access to effective treatments. A Breakthrough Therapies Research Advisory Board was also set up to monitor the program.

Access 97

Access Legalization Research and Development Legislation 97

PrestoDoctor

JANUARY 30, 2024

By exploring the signs and symptoms, risk factors, mechanism of action, and treatment options for cannabis-induced psychosis, we can better equip ourselves with the knowledge needed to prevent and manage this condition. In terms of treatment, a combination of medication and psychological interventions is common.

Research and Development 52

Research and Development Treatment Conditions Education 52

Cannabis Law Report

SEPTEMBER 23, 2022

Going forward, MAPS will focus on advocating for psychedelic policy reform to include state funding for public education, harm reduction, and unarmed crisis response services. On the heels of the update about SB 519 was news of Governor Gavin Newsom vetoing another proposed piece of drug policy legislation sponsored by Senator Wiener.

Decriminalization 52

Decriminalization Advocacy Research and Development Education 52

Veriheal

AUGUST 24, 2022

This campaign was backed by New Approach PAC, a nationwide political organization that is focused on supporting progressive reform surrounding cannabis and criminal justice policies. In May 2022, Connecticut’s governor signed a budget bill that included a provision for the implementation of psychedelic-assisted therapy treatment centers.

Legalization 108

Legalization Medicine Decriminalization Research and Development 108

Cannabis Law Report

MAY 18, 2022

With few solutions in sight, there is a growing body of evidence that suggests that psychedelic-assisted therapy could provide a breakthrough in treating countless mental health ailments, such as depression, substance abuse disorders, and PTSD. The clinical evidence for psychedelic assisted therapy is accumulating.

Research and Development 52

Research and Development Therapy Treatment Policy 52

Cannabis Law Report

JANUARY 12, 2022

Today, Maya (Maya PBC) and the National Psychedelics Association (NPA) announced their partnership in support of the implementation of Oregon’s Measure 109, the first state-approved policy to allow the regulated use of psilocybin products in a facilitated setting. ABOUT THE NATIONAL PSYCHEDELICS ASSOCIATION.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Veriheal

OCTOBER 20, 2021

Always consult a physician before attempting psychedelic therapy. According to Dr. Maria Rahmandar , medical director of the substance use program at Lurie Children’s Hospital of Chicago, “The findings here are pretty consistent with what I see clinically. Cannabis and magic mushrooms for the win! A Magical Future.

Therapy 98

Therapy Microdosing Decriminalization Consumption 98

The Joint Blog

JANUARY 30, 2020

With the MLB easing its policy on marijuana use, players in the NFL are hoping that, and asking for their league to do the same. Now, former football players told Reuters a similar policy would be a positive step for management of chronic pain in the NFL. The bottom line is just to give players choices,” said Davis. “To

Policy 41

Policy Marijuana Chronic Pain Therapy 41

United Patients Group

APRIL 11, 2023

MD programs typically last for four years and consist of coursework and clinical rotations in various medical specialties. After completing an MD program, graduates must undergo a residency program that provides hands-on training and practical experience in their chosen field.

Education 52

Education Research and Development Therapy Programs 52

Cannabis Law Report

NOVEMBER 4, 2021

The Oregon Psilocybin Advisory Board (Advisory Board) held a meeting on October 27 to begin fine tuning recommendations for the first regulated psilocybin treatment model in the United States. This blog post will discuss the rulemaking timeline and provide updates regarding policy recommendations from the five subcommittees.

Law 52

Law Therapy Treatment Policy 52

MMJ Recs

JANUARY 20, 2024

Maryland, a trailblazer in progressive healthcare policies, has been part of this trend. Let’s take a closer look at medical marijuana laws in Maryland and how they affect those in need of MMJ treatment! As of the latest guidelines, patients are allowed to possess up to 1.5

Law 52

Law Marijuana Patients Chronic Pain 52

Veriheal

OCTOBER 26, 2021

Considering the virus has claimed the lives of almost 5 million people around the world, it’s no wonder researchers want to learn more about potential treatment and prevention strategies. Elected leaders and government officials scrambled for policy solutions, health treatments, and even basic protections.

Education 98

Education Programs Cannabis Treatment 98

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. In MAPS’ 36th year, we’ll learn if our second Phase 3 study of MDMA-assisted therapy for PTSD was successful. At 36, MAPS is now older than I was when I started MAPS at age 32.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

DECEMBER 1, 2021

Join Chacruna and mental health experts and activists, Allison Feduccia, PhD, Vilmarie Fraguada Narloch, PsyD, Kylea Taylor, MS, LMFT, and Emma Knighton, MA, LMHC, to discuss topics around standards of care and accountability for practitioners in the psychedelic-therapy space, addressing issues of power, hierarchy, and abuse.

Safety 52

Safety Medicine Therapy Research and Development 52

MMJ Recs

MARCH 2, 2024

Insider Tips for Ohio Medical Marijuana Dispensary Visits Join loyalty programs and follow dispensaries on social media platforms to access exclusive promotions and discounts. Observing discretion in discussions regarding medical conditions and treatment enhances privacy and respect among patrons.

Dispensary 52

Dispensary Patients Marijuana Education 52

Cannabis Law Report

JULY 1, 2021

The Project on Psychedelics Law and Regulation at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School will advance evidence-based psychedelics law and policy. POPLAR will publish original law and policy research. CR: Can you describe the existing landscape of psychedelics research?

Law 105

Law Research and Development Therapy DEA 105

Cannabis Law Report

MARCH 29, 2022

We are thrilled to have Michael’s expertise guiding the development of MDMA-assisted therapy for PTSD! Former Moderna Vice President and Managing Director for North America recruited to prepare MAPS PBC for patient access and commercialization of the first psychedelic-assisted therapy anticipated to be approved by the FDA.

Therapy 52

Therapy Pharmaceutical Clinical Trials Access 52

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] More recently, MDMA therapy has inched closer to FDA approval. For the regulated community, this is a trend worth watching.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

JULY 14, 2022

Register for our new digital learning program. Dear Sean, MAPS is excited to announce the launch of Psychedelic Fundamentals , an online psychedelic education program which provides people with accurate, evidence-based information about psychedelics. Let’s hope they include ethics somewhere on the course. Register Now.

Education 52

Education Research and Development History Programs 52

Canna Law Blog

FEBRUARY 8, 2022

At the time (March 2020), the NFL finally relaxed its marijuana and player testing policies. First-time offenders will be referred to treatment in a drug rehabilitation program, with the threat of game suspensions if they don’t participate.

Marijuana 81

Marijuana Therapy Cannabinoids Collective 81

Cannabis Law Report

JUNE 19, 2022

The new center is designed to formalize a network of experts across the university based in a range of academic departments as well as existing centers focused on drug policy and substance misuse prevention and recovery. Davis and Slot predicted that as things stand, these therapies could be federally approved in three to five years. “If

Education 52

Education Research and Development Therapy Clinical Trials 52

NORML

FEBRUARY 23, 2020

2227) is bipartisan legislation that removes marijuana from the Controlled Substances Act, thus decriminalizing the substance at the federal level and enabling states to set their own policies. The measure would permit physicians to recommend cannabis therapy to those diagnosed with an autism spectrum disorder as well as opioid use disorder.

Legislation 239

Legislation Patients Decriminalization Access 239

Canna Law Blog

FEBRUARY 19, 2020

They certainly do not yet resemble the second wave of “retail model” programs that became standard with medical and adult use cannabis. This type of proposal envisions psilocybin-assisted therapy in controlled environments. At some point, federal policy finally evolves and change becomes inevitable.

Decriminalization 111

Decriminalization Research and Development Therapy Pharmaceutical 111

NORML

FEBRUARY 8, 2019

Senator Ron Wyden introduced legislation in the Senate — The Marijuana Revenue and Regulation Act — to permit states to establish their own marijuana regulatory policies free from federal interference. House Bill 19-1028 would permit physicians to recommend cannabis therapy to those diagnosed with an autism spectrum disorder.

Legislation 173

Legislation Decriminalization Patients Access 173

Cannabis Law Report

NOVEMBER 19, 2021

MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD.

Research and Development 52

Research and Development Clinical Trials Therapy Pharmaceutical 52

The Cannigma

SEPTEMBER 13, 2021

Cannabis is legal for medical use in Israel and the country has implemented decriminalization policies for small-scale possession charges. The medical cannabis program in Israel is not as lenient as those in many other countries, and patients typically are required to attempt other medical treatments before cannabis is approved.

Legalization 97

Legalization Decriminalization Patients Cannabis 97

Cannabis Law Report

MAY 29, 2021

Treatment Specialists. Not all rehab centers offer the same programs, and some of them might be a wrong decision for the type of addictiveness you’re struggling with or your mental health at that point. Our advice is to talk to a counselor first before choosing a program that will fit your condition at that point.

Programs 88

Programs Therapy Education Treatment 88

Cannabis Law Report

JUNE 27, 2022

The news that is attached I replicate below, and I include as well a couple of newsletters from the American Bar Association Cannabis Law & Policy Committee that I Chair. The FDA and the FTC took joint enforcement action against seven CBD firms for making COVID-19 treatment claims. Smokable Hemp case Supreme Court.

Seed-To-Sale 52

Seed-To-Sale Hemp Retail Treatment 52

Cannabis Law Report

JUNE 25, 2021

This appointment is driven by the expansion of Awakn’s psychedelic drug and therapy development pipeline targeting Addiction. Shaun McNulty, Awakn’s Chief Scientific Officer, who leads Awakn’s Pre-Clinical stage and Clinical stage research and development programs. David Nutt, has joined its executive team as Chief Research Officer.

Research and Development 66

Research and Development Therapy Medicine Pets 66